High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?
Basic & Clinical Pharmacology & Toxicology · 2025-07 · 137 (1)
DOI: 10.1111/bcpt.70070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 13.06.2025. Verfasst von Neha Wadhavkar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Sucralfate, Anti-Ulcer Agents, Gastrointestinal Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Sucralfate is a commonly prescribed medication in use for decades. Despite the availability of more effective medications for acid‐dyspeptic conditions, including proton pump inhibitors and histamine H2‐receptor antagonists, sucralfate continues to be utilized for upper gastrointestinal symptoms. We reviewed the limited evidence base supporting the approval and ongoing usage of sucralfate and performed a cost analysis using the ClinCalc database. The financial impact of sucralfate was comparable to famotidine, lansoprazole and ranitidine. We encourage further studies to accurately gauge the true clinical efficacy of sucralfate and to question its ongoing prescription until then.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Brown University, Providence, Rhode Island, USA.
- UMass Memorial Specialty Pharmacy, UMass Memorial Medical Center, Worcester, Massachusetts, USA.
- Division of Gastroenterology, Brown University, Providence, Rhode Island, USA.
ORCID-Profile: Neha Wadhavkar
Zitieren
APA
Wadhavkar, N., Varnum, L., & Moss, S. F. (2025). High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?. Basic & Clinical Pharmacology & Toxicology, 137(1). https://doi.org/10.1111/bcpt.70070
Vancouver
Wadhavkar N, Varnum L, Moss SF. High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?. Basic & Clinical Pharmacology & Toxicology. 2025;137(1). doi:10.1111/bcpt.70070
BibTeX
@article{Wadhavkar2025,
author = {Wadhavkar, Neha and Varnum, Laura and Moss, Steven F},
title = {High Economic Burden Yet Low Clinical Value: Why Is so Much Sucralfate Prescribed?},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2025},
volume = {137},
number = {1},
doi = {10.1111/bcpt.70070}
}
EUVIMED